ActiGraph Partners with VivoSense
ActiGraph, the provider of medical-grade wearable activity and sleep monitoring solutions, has announced a new partnership with data analytics specialist VivoSense. The partnership will allow both companies to deliver sponsor access to secure, regulated, analyzed, and contextualized sensor data from patients participating in pharmaceutical clinical trials. VivoSense is a regulatory compliant, cloud based platform for the analysis of wearable sensor data. VivoSense with VivoCapture provides pharmaceutical sponsors with access to contextualized sensor data, metadata, analyzed, and raw signals. The platform makes use of Azure authentication and authorization, computing, and storage in a regulated sensor data warehouse.
ActiGraph’s wearable activity monitoring sensors provide pharma companies with levels of continuous, high-resolution physiologic data. The collection and accurate analysis of biometric data streams is vital in today’s clinical research and helps to accelerate study enrollment and patient engagement.
VivoSense analyzes data from any biometric sensor or combination of sensors to integrate, clean, analyze, and derive new biomarkers. The large physiological data-sets generated by these sensors help to monitor health and understand the effects of new medicines and therapies in development.
"Providing context to collected wearable sensor data empowers our clients to make better sense of the data and investigate novel disease endpoints,” said Dudley Tabakin, CEO and Co-founder of VivoSense. "Combining ActiGraph’s world-leading activity and sleep monitoring with other physiological measures, cleaned and analyzed by VivoSense, will provide context to all clinical trials measures."
For more information, visit www.actigraphcorp.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
